Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

被引：50

作者：

Attard, Gerhardt ^{[1
,2
,3
]}

Sydes, Matthew R. ^{[4
]}

Mason, Malcolm D. ^{[5
]}

Clarke, Noel W. ^{[6
]}

Aebersold, Daniel ^{[7
]}

de Bono, Johann S. ^{[1
,2
,3
]}

Dearnaley, David P. ^{[1
,2
,3
]}

Parker, Chris C. ^{[1
,2
,3
]}

Ritchie, Alastair W. S. ^{[4
]}

Russell, J. Martin ^{[8
]}

Thalmann, George ^{[9
]}

Cassoly, Estelle ^{[10
]}

Millman, Robin

Matheson, David

Schiavone, Francesca ^{[4
]}

Spears, Melissa R. ^{[4
]}

Parmar, Mahesh K. B. ^{[4
]}

James, Nicholas D. ^{[11
]}

机构：

[1] Inst Canc Res, London SW3 6JB, England

[2] Royal Marsden NHS Fdn Trust, London, England

[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[4] UCL, MRC, Clin Trials Unit, London, England

[5] Cardiff Univ, Sch Med, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales

[6] Christie NHS Fdn Trust, Dept Urol, Manchester, Lancs, England

[7] Univ Bern, Bern, Switzerland

[8] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland

[9] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland

[10] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland

[11] Univ Warwick, Warwick, England

来源：

EUROPEAN UROLOGY | 2014年 / 66卷 / 05期

关键词：

METASTATIC PROSTATE-CANCER; INCREASED SURVIVAL; INHIBITOR; RECEPTOR; ACETATE;

D O I：

10.1016/j.eururo.2014.05.038

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：799 / 802

页数：4

共 12 条

[1] Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade [J].

Arora, Vivek K. ;

Schenkein, Emily ;

Murali, Rajmohan ;

Subudhi, Sumit K. ;

Wongvipat, John ;

Balbas, Minna D. ;

Shah, Neel ;

Cai, Ling ;

Efstathiou, Eleni ;

Logothetis, Chris ;

Zheng, Deyou ;

Sawyers, Charles L. .

CELL, 2013, 155 (06) :1309-1322

[2] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[3] Overcoming mutation-based resistance to antiandrogens with rational drug design [J].

Balbas, Minna D. ;

Evans, Michael J. ;

Hosfield, David J. ;

Wongvipat, John ;

Arora, Vivek K. ;

Watson, Philip A. ;

Chen, Yu ;

Greene, Geoffrey L. ;

Shen, Yang ;

Sawyers, Charles L. .

ELIFE, 2013, 2

[4] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[5] NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen [J].

Dyer, Matthew ;

Rinaldi, Fiona ;

Adler, Amanda I. .

LANCET ONCOLOGY, 2012, 13 (08) :762-763

[6]

Efstathiou E, EUR UROL IN PRESS

[7]

James ND, 2013, EUR UROL SUPPL, V12, P129

[8] Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial [J].

James, Nicholas D. ;

Sydes, Matthew R. ;

Mason, Malcolm D. ;

Clarke, Noel W. ;

Anderson, John ;

Dearnaley, David P. ;

Dwyer, John ;

Jovic, Gordana ;

Ritchie, Alastair W. S. ;

Russell, J. Martin ;

Sanders, Karen ;

Thalmann, George N. ;

Bertelli, Gianfilippo ;

Birtle, Alison J. ;

O'Sullivan, Joe M. ;

Protheroe, Andrew ;

Sheehan, Denise ;

Srihari, Narayanan ;

Parmar, Mahesh K. B. .

LANCET ONCOLOGY, 2012, 13 (05) :549-558

[9] Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer [J].

O'Donnell, A ;

Judson, I ;

Dowsett, M ;

Raynaud, F ;

Dearnaley, D ;

Mason, M ;

Harland, S ;

Robbins, A ;

Halbert, G ;

Nutley, B ;

Jarman, M .

BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2317-2325

[10] Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial [J].

Parker, Christopher C. ;

Sydes, Matthew R. ;

Mason, Malcolm D. ;

Clarke, Noel W. ;

Aebersold, Daniel ;

de Bono, Johann S. ;

Dearnaley, David P. ;

Ritchie, Alastair W. S. ;

Russell, J. Martin ;

Thalmann, George ;

Parmar, Mahesh K. B. ;

James, Nicholas D. .

BJU INTERNATIONAL, 2013, 111 (05) :697-699

← 1 2 →